8-K: Xeris Biopharma Sues Generic Makers Over Recorlev Patents

Xeris Biopharma subsidiaries have filed a patent infringement lawsuit against two generic drug companies to protect its Recorlev intellectual property until 2040.

Summary

• Xeris Biopharma Holdings, Inc. subsidiaries, Xeris Pharmaceuticals, Inc. and Strongbridge Dublin Limited, initiated a patent infringement lawsuit.
• The lawsuit, filed under the Hatch-Waxman Act, targets Torrent Pharmaceuticals Limited and Somerset Therapeutics, LLC.
• The defendants filed Abbreviated New Drug Applications (ANDAs) seeking approval for generic versions of Xeris's drug, RECORLEV (levoketoconazole).
• Xeris seeks an injunction to prevent the manufacture, use, and sale of generic RECORLEV until the expiration of its patents in March 2040.
• The lawsuit covers four Orange Book listed patents (U.S. Patent Numbers 11,020,393, 11,278,547, 11,903,940, and 12,377,096) which expire in March 2040.
• RECORLEV also has Orphan Drug Exclusivity through December 2028.
• The ANDA filers allege that Xeris's patents are invalid, unenforceable, or will not be infringed by their generic products.
• Xeris intends to vigorously defend its intellectual property rights and anticipates potentially receiving additional Notice Letters from other ANDA filers.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a defensive action against a significant threat to a key product's revenue stream. While the company is fighting back, the existence of the generic challenge itself is a negative development, introducing uncertainty and potential future revenue loss.

Positives

• Xeris is actively defending its intellectual property rights for RECORLEV, a key commercial product.
• The company expresses confidence in the quality and strength of its patents, which extend until March 2040.
• RECORLEV benefits from Orphan Drug Exclusivity until December 2028, providing an additional layer of market protection.

Negatives

• The filing of ANDAs by generic manufacturers indicates a direct challenge to RECORLEV's market exclusivity.
• The lawsuit will incur legal costs and divert management attention.
• There is a risk that the patents could be found invalid, unenforceable, or not infringed, potentially leading to earlier generic competition.
• Xeris anticipates receiving additional Notice Letters from other ANDA filers, suggesting a broader threat of generic competition.

Risks

• Litigation Outcome: The lawsuit's outcome is uncertain; patents could be deemed invalid, unenforceable, or not infringed, leading to earlier generic market entry.
• Future ANDA Filings: Xeris expects to receive additional Paragraph IV Certification Notice Letters from other ANDA filers, indicating ongoing threats to RECORLEV's exclusivity.
• Legal Costs: Defending intellectual property rights through litigation can be costly and time-consuming.
• Impact on Revenue: If generic versions of RECORLEV are approved and launched before patent expiration, Xeris's revenue from RECORLEV could be significantly impacted.

Future Outlook

Xeris intends to vigorously enforce and defend its intellectual property rights related to Recorlev, including through the pending litigation. The company anticipates potentially receiving additional Notice Letters from other ANDA filers in the future and plans to defend its IP against such challenges.

Management Comments

• "We are confident in the quality and strength of the intellectual property we have developed for Recorlev."
• "We have filed this patent infringement lawsuit to vigorously defend our position."

Industry Context

StockSavvy.ai notes that patent infringement lawsuits under the Hatch-Waxman Act are a common strategy for branded pharmaceutical companies to defend their market exclusivity against generic challengers. This action by Xeris is typical for a biopharma company seeking to protect a key revenue-generating product like Recorlev, especially given the significant investment in drug development and the value of extended patent protection. The challenge from multiple ANDA filers highlights the attractiveness of the Recorlev market for generic manufacturers.

Legal Proceedings

• Xeris Pharmaceuticals, Inc. and Strongbridge Dublin Limited have filed a patent infringement lawsuit against Torrent Pharmaceuticals Limited and Somerset Therapeutics, LLC.
• The lawsuit, filed in the U.S. District Court for the District of New Jersey, is under the Hatch-Waxman Act.
• It seeks an injunction to prevent the generic manufacture, use, or sale of RECORLEV until March 2040.
• The defendants allege that Xeris's four Orange Book listed patents for RECORLEV are invalid, unenforceable, or not infringed.

Stakeholder Impact

• Shareholders: Potential for increased legal costs and uncertainty regarding future RECORLEV revenue, which could impact stock performance. Conversely, successful defense of patents could protect long-term value.
• Customers (Patients): Potential for lower-cost generic versions of RECORLEV in the future if generics are successful, or continued access to branded RECORLEV if patents are upheld.
• Competitors (Generic Manufacturers): The lawsuit directly impacts Torrent Pharmaceuticals Limited and Somerset Therapeutics, LLC, potentially delaying their entry into the levoketoconazole market.

Next Steps

• Xeris will proceed with the patent infringement lawsuit in the U.S. District Court for the District of New Jersey.
• The company intends to enforce and defend its intellectual property rights relating to Recorlev against current and potential future ANDA filers.

Key Dates

Recommendation

While Xeris is taking appropriate legal action to defend its intellectual property, the initiation of a patent infringement lawsuit by generic manufacturers against a key product like Recorlev introduces significant uncertainty and potential downside risk. The outcome of such litigation is never guaranteed, and a loss could lead to earlier-than-expected generic competition, impacting future revenues. However, the company's stated confidence and the existence of patents until 2040, along with Orphan Drug Exclusivity until 2028, provide a basis for defense. An investor should hold, awaiting further developments in the legal proceedings and assessing the potential impact on Recorlev's market exclusivity and the company's overall financial outlook.

Keywords

Xeris Biopharma, RECORLEV, levoketoconazole, patent infringement, Hatch-Waxman Act, ANDA, generic drugs, intellectual property, biopharmaceutical, Orphan Drug Exclusivity, litigation